SP6616

a Kv2.1 channel inhibitor; structure in first source

Also Known As:

ethyl 5-(3-ethoxy-4-methoxyphenyl)-2-(4-hydroxy-3-methoxybenzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-(1,3)thiazolo(3,2-a)pyrimidine-6-carboxylate

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

1.	Mitochondrial Diseases (Mitochondrial Disease) 11/01/2020 - "In addition, SP6616 improved mitochondrial dysfunction through Kv2.1/CaMKKβ/AMPK/PGC-1α pathway, repressed inflammatory response by inhibiting Kv2.1/NF-κB signaling and alleviated apoptosis of DRG neuron through Kv2.1-mediated regulation of Bcl-2 family proteins and Caspase-3 in diabetic mice. "
2.	Peripheral Nervous System Diseases (PNS Diseases) 11/01/2020 - "SP6616 as a Kv2.1 inhibitor efficiently ameliorates peripheral neuropathy in diabetic mice."
3.	Type 2 Diabetes Mellitus (MODY) 01/01/2016 - "In addition, our study has also highlighted the potential of SP6616 in the treatment of type 2 diabetes."
4.	Nervous System Diseases (Neurological Disorders) 11/01/2020 - "As Kv2.1 channel functions potently in regulating neurological disorders, the present work was to investigate the regulation of Kv2.1 channel against DPN-like pathology of DPN model mice by using selective Kv2.1 inhibitor SP6616 (ethyl 5-(3-ethoxy-4-methoxyphenyl)-2-(4-hydroxy-3-methoxybenzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate) as a probe. "
5.	Hyperalgesia 11/01/2020 - "Amelioration of SP6616 on the pathological behaviors of diabetic mice was assessed against tactile allodynia, thermal sensitivity and motor nerve conduction velocity (MNCV). "